{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:56Z","timestamp":1793812436571,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00198-022-06626-1","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:02:53Z","timestamp":1671271373000},"page":"641-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A systematic review of cost\u2011effectiveness analyses of sequential treatment for osteoporosis"],"prefix":"10.1007","volume":"34","author":[{"given":"Guangyi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiju","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-4462","authenticated-orcid":false,"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"1","key":"6626_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312","journal-title":"Osteoporos Int"},{"issue":"3","key":"6626_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical practice Postmenopausal Osteoporosis. N Engl J Med 374(3):254\u2013262","journal-title":"N Engl J Med"},{"key":"6626_CR3","first-page":"154","volume":"34","author":"A Rashki Kemmak","year":"2020","unstructured":"Rashki Kemmak A et al (2020) Economic burden of osteoporosis in the world: a systematic review. Med J Islam Repub Iran 34:154","journal-title":"Med J Islam Repub Iran"},{"issue":"4","key":"6626_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","volume":"63","author":"M Munoz","year":"2020","unstructured":"Munoz M, Robinson K, Shibli-Rahhal A (2020) Bone health and osteoporosis prevention and treatment. Clin Obstet Gynecol 63(4):770\u2013787","journal-title":"Clin Obstet Gynecol"},{"key":"6626_CR5","doi-asserted-by":"crossref","unstructured":"Management of Osteoporosis in Postmenopausal Women: The Position Statement of The North American Menopause Society'' Editorial, P (2021) Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28(9): 973\u2013997.","DOI":"10.1097\/GME.0000000000001831"},{"key":"6626_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","volume":"87","author":"EM Curtis","year":"2016","unstructured":"Curtis EM et al (2016) Epidemiology of fractures in the United Kingdom 1988\u20132012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87:19\u201326","journal-title":"Bone"},{"issue":"3","key":"6626_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-018-00512-x","volume":"104","author":"JA Kanis","year":"2019","unstructured":"Kanis JA et al (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104(3):235\u2013238","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"6626_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A et al (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11(5):485\u2013497","journal-title":"Appl Health Econ Health Policy"},{"key":"6626_CR9","unstructured":"Chinese Medical Association (2019) Epidemiological survey of osteoporosis in China and \u201cHealthy Bones\u201d special action results released."},{"issue":"41","key":"6626_CR10","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.2174\/1381612823666170516124224","volume":"23","author":"H Liu","year":"2017","unstructured":"Liu H, Li B (2017) Prospect of combination and sequential therapies for postmenopausal osteoporosis. Curr Pharm Des 23(41):6251\u20136255","journal-title":"Curr Pharm Des"},{"key":"6626_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","volume":"71","author":"C Cheng","year":"2020","unstructured":"Cheng C, Wentworth K, Shoback DM (2020) New Frontiers in Osteoporosis Therapy. Annu Rev Med 71:277\u2013288","journal-title":"Annu Rev Med"},{"issue":"4","key":"6626_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging-Clinical & Experimental Research 34(4):695\u2013714","journal-title":"Aging-Clinical & Experimental Research"},{"key":"6626_CR13","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516","journal-title":"Bone"},{"key":"6626_CR14","first-page":"227","volume":"143","author":"HM Frost","year":"1979","unstructured":"Frost HM (1979) Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res 143:227\u2013244","journal-title":"Clin Orthop Relat Res"},{"issue":"10","key":"6626_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrendo.2015.134","volume":"11","author":"B Abrahamsen","year":"2015","unstructured":"Abrahamsen B (2015) Bone: sequential osteoporosis treatment\u2013the order of things. Nat Rev Endocrinol 11(10):570\u2013572","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"6626_CR16","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1210\/jc.2012-1844","volume":"97","author":"AL Schafer","year":"2012","unstructured":"Schafer AL et al (2012) Six months of parathyroid hormone (1\u201384) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab 97(10):3522\u20133529","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6626_CR17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J et al (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30(7):1465\u20131473","journal-title":"Osteoporos Int"},{"issue":"2","key":"6626_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14656566.2017.1418857","volume":"19","author":"JY Reginster","year":"2018","unstructured":"Reginster JY et al (2018) Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 19(2):159\u2013161","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"6626_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M et al (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205\u2013224","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"6626_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N et al (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39(2):181\u2013209","journal-title":"Pharmacoeconomics"},{"key":"6626_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"6626_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25(1):3\u20139","journal-title":"Value Health"},{"issue":"Suppl 1","key":"6626_CR23","first-page":"71","volume":"31","author":"World Congress on Osteoporosis","year":"2020","unstructured":"World Congress on Osteoporosis (2020) Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2020): ESPRM-ESCEO-IOF symposium abstracts. Osteoporos Int 31(Suppl 1):71\u201373","journal-title":"Osteoporos Int"},{"issue":"2","key":"6626_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA et al (2019) Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother 53(2):134\u2013143","journal-title":"Ann Pharmacother"},{"issue":"3","key":"6626_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","volume":"32","author":"E Soreskog","year":"2021","unstructured":"Soreskog E et al (2021) Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int 32(3):585\u2013594","journal-title":"Osteoporos Int"},{"issue":"1","key":"6626_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11657-021-00891-z","volume":"16","author":"T Mori","year":"2021","unstructured":"Mori T et al (2021) Cost-effectiveness of sequential daily teriparatide\/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch Osteoporos 16(1):72","journal-title":"Arch Osteoporos"},{"key":"6626_CR27","doi-asserted-by":"publisher","first-page":"816248","DOI":"10.3389\/fphar.2022.816248","volume":"13","author":"R You","year":"2022","unstructured":"You R et al (2022) Cost-effectiveness of sequential denosumab\/zoledronic acid compared with zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Front Pharmacol 13:816248","journal-title":"Front Pharmacol"},{"issue":"11","key":"6626_CR28","doi-asserted-by":"publisher","first-page":"e10233","DOI":"10.1002\/jbm4.10233","volume":"3","author":"T Mori","year":"2019","unstructured":"Mori T, Crandall CJ, Ganz DA (2019) Cost-effectiveness of sequential teriparatide\/alendronate versus alendronate-alone strategies in high-risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide. JBMR Plus 3(11):e10233","journal-title":"JBMR Plus"},{"key":"6626_CR29","doi-asserted-by":"publisher","first-page":"794861","DOI":"10.3389\/fpubh.2022.794861","volume":"10","author":"R You","year":"2022","unstructured":"You R et al (2022) Cost-effectiveness of sequential teriparatide\/zoledronic acid compared with zoledronic acid monotherapy for postmenopausal osteoporotic women in China. Front Public Health 10:794861","journal-title":"Front Public Health"},{"issue":"3","key":"6626_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M et al (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture a US payer perspective. Semin Arthritis Rheum 50(3):394\u2013400","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"6626_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M et al (2019) Cost-effectiveness of sequential treatment with abaloparatide vs teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184\u2013196","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"6626_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11657-021-00956-z","volume":"16","author":"T Mori","year":"2021","unstructured":"Mori T et al (2021) Cost-effectiveness of zoledronic acid compared with sequential denosumab\/alendronate for older osteoporotic women in Japan. Arch Osteoporos 16(1):113","journal-title":"Arch Osteoporos"},{"issue":"10","key":"6626_CR33","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00198-021-05927-1","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H et al (2021) Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 32(10):2011\u20132021","journal-title":"Osteoporos Int"},{"issue":"2","key":"6626_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","volume":"26","author":"JE Stahl","year":"2008","unstructured":"Stahl JE (2008) Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 26(2):131\u2013148","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"6626_CR35","doi-asserted-by":"publisher","first-page":"e0246080","DOI":"10.1371\/journal.pone.0246080","volume":"16","author":"C Min","year":"2021","unstructured":"Min C et al (2021) An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics. PLoS ONE 16(2):e0246080","journal-title":"PLoS ONE"},{"issue":"2","key":"6626_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.afos.2020.05.006","volume":"6","author":"M Azharuddin","year":"2020","unstructured":"Azharuddin M et al (2020) Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: a quality appraisal. Osteoporos Sarcopenia 6(2):39\u201352","journal-title":"Osteoporos Sarcopenia"},{"issue":"10","key":"6626_CR37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52(10):1031\u20131041","journal-title":"Ann Pharmacother"},{"issue":"2","key":"6626_CR38","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2196\/jmir.3951","volume":"17","author":"S Hamine","year":"2015","unstructured":"Hamine S et al (2015) Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res 17(2):e52","journal-title":"J Med Internet Res"},{"issue":"1","key":"6626_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.11124\/jbisrir-2016-2296","volume":"14","author":"TT Ha Dinh","year":"2016","unstructured":"Ha Dinh TT et al (2016) The effectiveness of the teach-back method on adherence and self-management in health education for people with chronic disease: a systematic review. JBI Database System Rev Implement Rep 14(1):210\u2013247","journal-title":"JBI Database System Rev Implement Rep"},{"issue":"3","key":"6626_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","volume":"7","author":"P Pisani","year":"2016","unstructured":"Pisani P et al (2016) Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop 7(3):171\u2013181","journal-title":"World J Orthop"},{"issue":"4","key":"6626_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34(4):632\u2013642","journal-title":"J Bone Miner Res"},{"key":"6626_CR42","doi-asserted-by":"crossref","unstructured":"Hiligsmann, M., et al (2022) Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. Osteoporos Int","DOI":"10.1007\/s00198-022-06400-3"},{"issue":"2","key":"6626_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-016-3751-z","volume":"28","author":"W Ni","year":"2017","unstructured":"Ni W, Jiang Y (2017) Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model. Osteoporos Int 28(2):529\u2013538","journal-title":"Osteoporos Int"},{"issue":"12","key":"6626_CR44","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s40273-019-00835-z","volume":"37","author":"DM Sugrue","year":"2019","unstructured":"Sugrue DM et al (2019) Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. Pharmacoeconomics 37(12):1451\u20131468","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"6626_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1586\/14737167.2016.1165608","volume":"16","author":"JJ Caro","year":"2016","unstructured":"Caro JJ, Moller J (2016) Advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Rev Pharmacoecon Outcomes Res 16(3):327\u2013329","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"6626_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40273-021-01111-9","volume":"40","author":"R Milne","year":"2022","unstructured":"Milne R, Carswell C (2022) CHEERS to 30 years of pharmacoeconomics. Pharmacoeconomics 40(1):5\u20136","journal-title":"Pharmacoeconomics"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06626-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T09:08:03Z","timestamp":1679994483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06626-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6626"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06626-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}